anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Mild cognitive impairment is a common feature of Parkinson's disease (PD-MCI), even at the earliest disease stages. Growing evidence supports the instability of PD-MCI over time, without a consistent linear evolution to dementia, and in some patients, the potential of reversion to normal cognition. However, which features are associated with reversion from PD-MCI to normal cognition in early PD-MCI are not fully known.
METHODS: In our longitudinal study of early drug naïve PD patients, 65 of 134 (48 %) patients had PD-MCI at baseline. Study participants underwent comprehensive assessments at baseline and 1-year follow-up. Sixteen (24.6 %) patients with PD-MCI reverted to normal cognition (Reverters), and 49 (75.4 %) had persistent PD-MCI (Non-Reverters) after 1-year follow-up. We performed single- and multiple-variable logistic regression analyses to identify baseline variables predicting reversion of PD-MCI to normal cognition after 1-year. We also compared brain morphometric measures (cortical thickness and volumes) at baseline between the PD-MCI Reverters and Non-Reverters.
RESULTS: Higher educational level and better performance on measures of attention and memory at baseline predicted the reversion to normal cognition at 1-year follow-up. Reverters had greater cortical thickness in the left inferior temporal gyrus than Non-Reverters.
CONCLUSIONS: Our results show PD-MCI with a higher chance of reverting to normal cognition over time have a higher educational level, better frontotemporal-related cognitive function, and increased thickness of the inferior temporal lobe gyrus. These findings may potentially help researchers to select the candidates for clinical trials focusing on the treatment of cognitive impairment in the early stages of PD.
Prepn. of salts of 1-aryloxy-3-isopropylamino-2-propanol of formula (I) is claimed where R is H or methyl, n is 1 or 2, X is one of various acid radicals and A can be different types of radicals. Process comprises neutralising the parent cpds. with acid e.g. hydrochloric, tartaric, fumaric, etc. Process is suitably effected at ca. 50 degrees C, in nonbasic polar solvents.
Participants will contact the research team with the information on the flyer. Participants will be asked to come to the Iyengar Yoga Center (407 W Springfield Ave, Urbana, IL 61801) to receive more information. Participants will need to disclose their diagnosis to the research staff. If they are not aware of what their diagnosis is, they will need to contact their physician to get their official diagnosis. For example, a woman with dysmenorrhea may be diagnosed with poly cystic ovarian disease or endometriosis or idiopathic dysmenorrhea, or another reproductive disease; participants will need to know their specific diagnosis or find out their specific diagnosis and report it to the research staff. Participants can do this by calling their physicians. For participants that are unaware of their diagnosis, they may also request a copy of their medical records. These records may be shared with the research staff to help determine diagnosis. The research staff will not keep these medical records, but return them to the participants. Participants can then either consent on the first visit or choose to take time as much time as they need and return to the yoga center when they are ready to sign the consent form. Participants will complete the first round of surveys at the yoga center after they sign the consent form (20 minutes). Participants will receive an email or phone call from the study team to inform them of their randomization results.

A blind third party statistician will complete the randomization for all participants at the beginning of the study for all 90 participants and will email the study coordinator with the randomization results. Randomization will be done through a free online software called graphpad. (https://www.graphpad.com/quickcalcs/randomize1.cfm).

The study lasts 12 months for the intervention and 9 months for the control group with an optional 3 month yoga therapy session offered at the end: Once consented, participants will fill out baseline surveys, and then undergo 3 months of usual care (no intervention), the same baseline surveys will be filled out again, then participants will get biweekly free yoga therapy classes for 3 months, and surveys will again be completed at the end of the intervention. Patients will then have a 6 month follow up and will fill out the surveys one last time. Recruitment will occur on a rolling basis so patients may join the study at anytime and not have to wait for a batched group.
Patients receive 177Lu-PNT2002 IV over 1-10 minutes on days -112 and -56 in the absence of disease progression or unacceptable toxicity. Beginning on day 1, patients then undergo SBRT to all lesions for 1, 3, or 5 treatment doses (fractions) over the span of 10-20 days in the absence of disease progression or unacceptable toxicity.
A first object is to clarify a factor relating to the onset of arthritis, in particular, rheumatoid arthritis. Further, it is intended to provide a method of screening a remedy for arthritis targeting the factor thus found and a remedy and an examination reagent for arthritis. Compared with wild type mice, midkine-knockout mice show a significantly low incidence of arthritis. Most of patients suffering from arthritis show high midkine levels in the serum and synovial fluid. These facts suggest that the expression of midkine closely correlates to rheumatoid arthritis. The frequency of the onset of antibody-induced arthritis is elevated by administering midkine to midkine gene-deficient mice.
OBJECTIVE: To investigate the efficiency of high-intensity focussed ultrasound with intense pulsed light in the treatment of atrophic and icepick acne scars.
METHODS: The interventional study was conducted between November 2021 and April 2022 at the Postgraduate Medical Physics Laboratory, Mustansiriyah University, Baghdad, Iraq, and comprised patients with atrophic scars in group A and acne scars in group B. They were treated first with intense pulsed light and then with high-intensity focussed ultrasound. All patients received 4 treatment sessions spread over 4 weeks. Outcome assessment was done using Patient and Observer Scar Assessment Scale. Data was analysed using SPSS software version 24.
RESULTS: Of the 22 patients, 12(55%) were males with mean age 20.75±4.20 years, and 10(45%) were females with mean age 21±2.05 years. The combination technique showed significant outcomes compared to baseline (p<0.05). Atrophic scars exhibited significantly greater improvement compared to icepick scars (p<0.05). There was no significant difference between the overall opinion of the observer (p=0.3549) and the patients (p=0.0956).
CONCLUSIONS: The high-intensity focussed ultrasound and intense pulsed light techniques used in combination was found to be effective in treating atrophic and icepick scars.
PROBLEM TO BE SOLVED: To obtain a new condensed ring compound having cholesterol-lowering action and triglyceride-lowering action as well as low toxicity and safety and useful for preventing and treating hyperlipemia. SOLUTION: This compound is represented by formula I[R1 is H or a substitutable hydrocarbon; R2 is H, an aromatic heterocylic group, etc.; X is phosphoric acid group, sulfonic acid group, etc.; a ring A is a substitutable benzene ring or an aromatic heterocylic ring; a ring J is a 7-or 8-membered heterocyclic ring having <=3 hetero atoms as atoms constituting the ring; D is C or N; (n) is 1 or 2], e.g. [(3S, 5S)-7-chloro-5(2,3-dimethoxyphenyl)-1- neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzooxazepin-3-yl]methylphosph onic acid diazide. The compound is preferably obtained by reacting a compound of formula II (Y is an eliminable group) with a compound of the formula, P(OR3 )3 (R3 is a hydrocarbon) and further, as necessary, hydrolyzing the resultant compound. The compound of formula II is preferably obtained by using a compound of formula III as a starting raw material.
Hepatitis B virus (HBV) infection remains a significant global health challenge, with chronic HBV leading to severe liver diseases, including cirrhosis and hepatocellular carcinoma. Current treatments often fail to eradicate the virus, highlighting the need for innovative therapeutic strategies. The CRISPR/Cas9 system has emerged as a dynamic tool for precise genome editing and presents a promising approach to targeting and eliminating HBV infection. This review provides a comprehensive overview of the advances, challenges, and delivery strategies associated with CRISPR/Cas9-based therapies for HBV. We begin by elucidating the mechanism of the CRISPR/Cas9 system and then explore HBV pathogenesis, focusing on the role of covalently closed circular DNA (cccDNA) and integrated HBV DNA in maintaining chronic infection. CRISPR/Cas9 can disrupt these key viral reservoirs, which are critical for persistent HBV replication and associated liver damage. The application of CRISPR/Cas9 in HBV treatment faces significant challenges, such as off-target effects, delivery efficiency, and immune responses. These challenges are addressed by examining current approaches to enhance the specificity, safety, and efficacy of CRISPR/Cas9. A future perspective on the development and clinical translation of CRISPR/Cas9 therapies for HBV is provided, emphasizing the requirement for further research to improve delivery methods and ensure durable safety and effectiveness. This review underscores the transformative potential of CRISPR/Cas9 in combating HBV and sets the stage for future breakthroughs in the field.
Participants will be directed to use portion control to maintain a calorie level no greater than 1120 kcal per day. The participants will be directed to continue to consume food and beverage items that are representative of their typical diet (with the exception of reduced portions). Participants will be provided resources to assist them in determining caloric content of foods eaten.
Provided are anticancer compositions comprising the alcohol extract of Pueraria sp. root. The compositions have excellent anticancer effects with less adverse side effects and is thus useful for prevention and treatment of various kinds of cancers. Therefore, the compositions are applied to anticancer-pharmaceuticals and cosmetics. The cosmetic composition comprises, as an active ingredient, the alcohol extract of Pueraria sp. root, wherein Pueraria sp. includes Pueraria mirifica and Pueraria lobata. The alcohol extract is at least one kind selected from PE1, PE2, PE3, PE4, Sub PE-A, Sub PE-B, Sub PE-C, Sub PE-D, Sub PE-E, Sub PE-F, Sub PE-G, Sub PE-H, Sub PE-D1, Sub PE-D2 and Sub PE-D3. The extract inhibits the proliferation of cancer cells to prevent and treat cancers. And it has skin stability, increases skin elasticity, has skin moisturizing effect and prevents skin wrinkles.
PURPOSE: Despite lung cancer is one of the leading causes of cancer-related deaths, it remains hard to discover effective diagnostic and therapeutic approaches. Moreover, the five-year survival rate is relatively lower than other tumors. So urgent needs for finding a new theranostic target to treat lung cancer effectively. This study aims to present SOCS3 and NOD2 proteins as novel targets for diagnosis and therapy.
METHODS: We first confirmed SOCS3 expression level in patients' tissues. Then, we applied knockdown and overexpression of SOCS3 on lung cancer cell lines and performed proliferation, migration, and invasion assay. After that, we found NOD2 is a target of SOCS3 and introduced overexpression of NOD2 to A549 for verifying reduced tumorigenicity of lung cancer cells.
RESULTS: We identified protein expression level of SOCS3 was frequently higher in tumor tissues than adjacent normal tissues. Truly, overexpression of SOCS3 promoted proliferation, migration, and invasion capacity of lung cancer cells. We found that SOCS3 interacts with NOD2 and SOCS3 ubiquitinates NOD2 directly. Furthermore, lung cancer tissues with higher SOCS3 expression showed lower NOD2 expression. We confirmed overexpression of NOD2 leads to suppressed tumorigenicity of lung cancer cells, and these effects occurred through MAPK pathway.
CONCLUSION: Collectively, our work reveals novel roles of SOCS3 in lung tumorigenesis and proposes SOCS3 as a promising biomarker candidate for therapeutic and diagnostic target for lung cancer.
Those in Group 2 (control group) will not be provided with the "Free From Pain Exercise Book", and will instead be referred to physiotherapy as part of standard / usual care. They will be asked to report when their physiotherapy commenced.
PURPOSE:To obtain the titled pharmaceutical useful as a remedy for angina pectoris, etc. industrially and advantageously, by adding an acrylic acid resin as a sustained releasing agent in a specific proportion in the form of a solution or dispersion to mixed powder of diltiazem hydrochloride and an excipient and granulating the resultant mixture. CONSTITUTION:An acrylic acid resin, e.g. a copolymer of methyl methacrylate and methacrylic acid, etc., as a sustained releasing agent in an amount of about 5-20% based on the weight of the aimed pharmaceutical is incorporated in diltiazem hydrochloride to afford the titled pharmaceutical. Specifically, diltiazem is incorporated with an excipient, preferably lactose, and an acrylic acid resin solution or dispersion is added to granulate the resultant mixture. The resultant granulated material can be dried, mixed with a lubricant and molded to afford industrially and advantageously the pharmaceutical. The addition of a small amount of the acrylic acid resin permits effective sustained release of the diltiazem hydrochloride and the effective concentration in blood can be maintained for a long period.
PURPOSE: A drug-containing mucous membrane adhesive formulation is provided to prevent easy dissolution by saliva and treat stomatitis. CONSTITUTION: A mucous membrane adhesive formulation contains drug-containing mucous membrane adhesive layer and drug protection support layer. The drug-containing mucous membrane adhesive layer comprises hydrogel which is cross-lined by irradiating radiation to mucous membrane adhesive polymer solution. A drug protection support layer comprises a hydrogel in which mucous membrane non-adhesive polymer solution is applied and dried at one side of the adhesive layer. The mucous membrane adhesive polymer is selected from polyacrylic acid, polymethaacrylic acid, and sodium polyacrylate. The mucous membrane non-adhesive polymer is polymethacrylic acid polymer.
AIM: This study aimed to assess the impact of routine histological examination of stapled colorectal anastomotic doughnuts in patients undergoing rectal cancer surgery (RCS). Justification of biopsy examination could form part of the strategies of NHS net zero practice with effort to reduce wastage and carbon footprint.
METHOD: A data analysis of all patients undergoing RCS during 2019-2021 at our institute was performed. We also analysed the cost of preparing and reviewing histology slides.
RESULTS: 52 patients underwent anterior resection during the aforementioned period. Doughnuts were sent in 37 (71%) patients. 23 (62%) patients were male, and 14 (38%) were female. The median age at diagnosis was 68 (range 54-84) years. All resected specimens were adenocarcinomas. Of the 37 patients, 18 (49%) underwent low anterior resection and 19 (51%) underwent high anterior resection. Proximal doughnuts were sent in 26 (70%) patients, whereas distal doughnuts were sent in all cases. Mean distal microscopic resection margin from tumour was 22 mm (range 6-45 mm). Each doughnut required 3 slides, each costing £50 and requiring 82 minutes to fix and read. This incurred a cost of £13,650 and required 19,656 hours of preparation time. All of the doughnuts as well as resection margins were negative for malignancy.
CONCLUSION: Routine histopathological examination of doughnuts is time and cost-intensive however provides little or no clinical value (particularly analysis of the proximal doughnut). Distal doughnuts should only be sent for histological examination in exceptional circumstances.
This is a pre-experimental "one group pretest-posttest" design to increase COVID-19 vaccine uptake and completion among African American and Latinx public housing residents in South Los Angeles. The proposed intervention will employ (1) culturally sensitive, (2) theoretically based intervention that will be jointly delivered by our ACTIVATE triad leaders and our researchers. We will use the Information, Motivation, and Behavioral Skills (IMB) model and the Transtheoretical Model to implement the intervention.
BACKGROUNDS: Cognitive problems are common symptoms among individuals with stress-related exhaustion. It is still unknown whether these individuals are at a higher risk of developing dementia later. This study aims to examine the relationship between midlife stress-related exhaustion and dementia incidence.
METHODS: A population sample of 777 women (aged 38, 46, 50 and 54 years) without dementia at baseline was followed over 50 years, from 1968 to 2019. Stress-related exhaustion was based on information from the psychiatric examination in 1968/69. Information on dementia incidence between 1968 and 2019 was obtained from neuropsychiatric examinations, key-informant interviews, and hospital registry. Dementia was diagnosed according to the DSM-III-R criteria. A subgroup of non-demented women (n = 284) was examined for cognitive functions by the Gottfries-Bråne-Steen scale 24 years after baseline.
RESULTS: Stress-related exhaustion in midlife was associated with higher risk for development of dementia before age 75 (Hazard ratio and 95% confidence interval: 2.95 and 1.35-6.44). The association remained after adjustment for age, major depression, and anxiety disorder. Mean age of dementia onset was younger for women with stress-related exhaustion than women without stress (mean ± SD, 76 ± 9 vs. 82 ± 8 . p = 0.009). Women with stress-related exhaustion in midlife still showed more cognitive impairments 24 years later compared with women without stress (Odds ratio and 95% confidence interval: 2.64 and 1.15-6.06).
CONCLUSIONS: We found that women with stress-related exhaustion in midlife were at a higher risk to develop dementia at relatively younger age. These women showed persistently lower cognitive functions over years even without dementia. Present study results need to be interpreted with caution due to small sample size and should be confirmed in future studies with larger sample size. Our study findings may imply the importance of long-term follow-up regarding cognitive function among individuals with stress-related exhaustion.
A method and pharmaceutical composition for inhibiting translation in sperm cells during capacitation. The pharmaceutical composition comprises a substance that is an inhibitor of translation by 55S, 70S-like, or mitochondrial ribosomes. The substance may be, for example, D-Chloramphenicol, gentamycin, or tetracycline. The substance may also be a polynucleotide that is antisense to a sperm mRNA that is transcribed by 55S, 70S-like, or mitochondrial ribosomes, or a ribonucleozyme that cleaves a sperm mRNA that is transcribed by 55S, 70S-like, or mitochondrial ribosomes. Such an mRNA may be, for example, a sperm mRNA encoding for AT1-R, PKC , Progesterone receptor, Catsper1 or Na-K ATPase 4. The method of the invention comprises administering to sperm cells the pharmaceutical composition of the invention. The method may be used for inhibiting capacitation in sperm cells or for inhibiting a capacitation dependent process in sperm cells such as acrosome reaction, motility, oocyte penetration, in vitro fertilization or in vivo fertilization.
Sample and procedure In the first study we collected 1 mL of unstimulated whole saliva by spitting participants into a sterile Eppendorf tube at baseline and 5 min after rinsing with 5 mL of 4 different types of commercially available mouthwashes from identical opaque-coded flasks. From our clinical ambulance randomly selected 145 patients assessed for eligibility. Inclusion criteria were: DMF≥10, minimum 5 active caries and PSR≥2. Exclusion criteria were: smoking, a history of antibiotic, or probiotic use 3 months prior to sampling, or known allergy to any of the ingredients of mouthwashes being tested. Twenty five patients were excluded (19 of these based on the criteria above and 6 refused to participate). One hundred and twenty volunteering patients (42±8 years) with poor oral hygiene were selected to participate in the study. All eligible subjects were given oral and written information about the products and the purpose of the study and were asked to sign an informed consent form. Volunteers were randomly assigned to the tests and the positive control (Corsodyl®) groups. Randomization was performed using computer-generated random numbers. The randomization and the allocation of rinse aids were carried out by a person not directly involved in the research project. The volunteers rinsed for 1 min, with a 20-fold dilution of hyper-pure 0.03 % ClO2 (Solumium Oral®, final concentration: 0.0015%), Corsodyl® (0.2% CHX), Listerine Total Care® (essential oils, sodium fluoride, zinc chloride), or BioGate Si\*CLEAN® (microsilver) (30 individuals in each mouthwash group).

In the second study randomly chosen 26 medical student volunteers (20±3 years) rinsed with 5 mL of 10-fold diluted hyper-pure ClO2 (final concentration: 0.003%) or Corsodyl® for 1 min, and their unstimulated whole saliva was collected as above at base line and after 5 and 90 minutes (13 individuals in each mouthwash group). The restrictions on the oral hygiene of the volunteers were: DMF≥5, minimum 1 active caries, PSR≥1 and exclusion categories were the same as in the first study. The management of eligible subjects, their randomization and the allocation of rinse aids in same opaque-coded flasks were also exactly identical to the first study. Eleven volunteers were excluded from this study (9 of these based on the criteria above and 2 refused to participate).

The saliva samples were stored in Eppendorf tubes used for collection at air-conditioned room temperature and processed within two hours. A dilution series was prepared from the samples in physiological salt solution. To determine our pre-specified primary outcome, the total bacterial count and the S. mutans number (CFU/ml) blood and Mitis-Salivarius (Difco, Becton-Dickinson, Hungary) agars were inoculated, respectively. Cultivation was carried out at 37 °C, 5 % CO2 and took 2 days. The CFU counting researcher did not know which plates were exposed to each treatment.
Subjects will receive subcutaneous treatment of 300mg of omalizumab during the 24-week treatment period. One injection will be administered every 4 weeks.
Part A participants with a quantifiable (i.e. positive) result for buprenorphine and/or norbuprenorphine and a non-quantifiable (i.e. negative) result for naloxone continue in the study for two additional visits (Visits 2 and 3) which are conducted approximately 30 days apart during which blood and urine samples are collected.